Internal Medicine, Infectious Disease · Norwalk, CT
NPI
1003857616
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
618 West Ave
Norwalk, CT, 06850
Phone (203) 852-9525
Groups this clinician bills Medicare through
Medicare paid, 2024
$30K
2,083 services
Medicare patients, 2024
71
Average age 66
Drug cost, 2024
$2.6M
2,852 prescriptions
Company payments, 2025
$110K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David S Rubin was code 99214 (office e&m - established), 70 times for 43 patients. In total David S Rubin billed 2,083 services in 26 codes, and Medicare paid $30K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 70 | 43 | $86.59 | $6,061 |
| 99213 Office E&M - Established | Office | 54 | 37 | $61.09 | $3,299 |
| 99212 Office E&M - Established | Office | 24 | 17 | $44.12 | $1,059 |
By year: 2022 $12K for 406 services; 2023 $28K for 718 services; 2024 $30K for 2,083 services.
Medicare prescription drug claims, 2024
In 2024, the drug David S Rubin prescribed most often to Medicare patients was Dovato (Dolutegravir Sodium/Lamivudine), with 162 prescriptions and refills. In total David S Rubin wrote 2,852 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dovato Dolutegravir Sodium/Lamivudine | 162 | 176 | 15 | $490K |
| Atorvastatin Calcium Generic | 126 | 181 | 18 | $565 |
| Descovy Emtricitabine/Tenofov Alafenam | 125 | 143 | 17 | $297K |
| Rosuvastatin Calcium Generic | 88 | 162 | 19 | $916 |
| Valacyclovir Valacyclovir Hcl | 88 | 102 | 13 | $2,353 |
| Tivicay Dolutegravir Sodium | 83 | 97 | Under 11 | $251K |
| Juluca Dolutegravir/Rilpivirine | 74 | 88 | Under 11 | $291K |
| Amlodipine Besylate Generic | 71 | 110 | 12 | $379 |
| Farxiga Dapagliflozin Propanediol | 63 | 73 | Under 11 | $41K |
| Testosterone Generic | 58 | 63 | 12 | $5,957 |
| Tadalafil Generic | 53 | 53 | Under 11 | $708 |
| Egrifta Sv Tesamorelin Acetate | 48 | 48 | Under 11 | $332K |
| Tamsulosin Hcl Generic | 44 | 58 | Under 11 | $437 |
| Doxycycline Hyclate Generic | 41 | 41 | 23 | $327 |
| Lisinopril Generic | 39 | 52 | Under 11 | $143 |
Brand drugs: 1,088 claims; generic drugs: 1,750 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David S Rubin $110K ($110K in general payments such as food, travel and fees) from 11 companies. The largest payer was ViiV Healthcare Company with $56K.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 95 | $56K |
| Gilead Sciences, Inc. GILD | 76 | $53K |
| Abbvie Inc. ABBV | 7 | $138 |
| Merck Sharp & Dohme LLC MRK | 6 | $118 |
| Theratechnologies Inc. THTX | 4 | $102 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $80.92 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 4 | $69.36 |
| Pfizer Inc. PFE | 2 | $33.73 |
| Paratek Pharmaceuticals, Inc. | 1 | $20.06 |
| Exact Sciences Corporation EXAS | 1 | $15.73 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.